Other Events On November 2, 2026, Myriad Genetics, Inc. (the “Company”) detected unauthorized access within its information technology network environment. Upon discovery, the Company promptly initiated its incident response procedures to contain the activity, assess and investigate the nature and scope of the incident, and implement appropriate remedial measures, including temporarily suspending its testing operations and order management systems and resetting certain system credentials. The…

Results of Operations and Financial Condition. On November 4, 2026, Myriad Genetics, Inc. announced its financial results for the three months ended September 30, 2026. The earnings release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements . Except for historical information contained in this Current Report on Form 8-K, including Exhibit 99.1, this Current Report on Form 8-K, includi…

Entry into a Material Definitive Agreement. On October 19, 2026, Myriad Genetics, Inc., a Delaware corporation (the “Company”), and Laboratory Corporation of America, a Delaware corporation (“Buyer”), entered into an Asset Purchase Agreement (the “Purchase Agreement”). Pursuant to the Purchase Agreement, the Company has agreed to sell and assign to Buyer, and Buyer has agreed to purchase and assume from the Company, certain assets and liabilities of the Company’s prenatal health business, inc…

Chief Commercial Officer — Brian Donnelly: The filing discloses the formal separation agreement and severance details for the former Chief Commercial Officer, confirming his departure from the company.

Chief Commercial Officer — Vishal Sikri: The filing primarily discloses the internal promotion of Vishal Sikri to Executive Vice President, Commercial, to succeed Brian Donnelly, who is transitioning out of the CCO role.

Results of Operations and Financial Condition. On July 30, 2026, Myriad Genetics, Inc. announced its financial results for the three months ended June 30, 2026. The earnings release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements . Except for historical information contained in this Current Report on Form 8-K, including Exhibit 99.1, this Current Report on Form 8-K, including Exhib…

Director — Daniel M. Skovronsky M.D., Ph.D.: Dr. Skovronsky resigned as a director without any disagreement or issues with the company.

The filing primarily concerns stockholder approvals for equity incentive plans and amendments to existing plans.

Results of Operations and Financial Condition. On May 5, 2026 , Myriad Genetics, Inc. announced its financial results for the three months ended March 31, 2026. The earnings release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements . Except for historical information contained in this Current Report on Form 8-K, including Exhibit 99.1, this Current Report on Form 8-K, including Exhib…

Results of Operations and Financial Condition. On February 23, 2026 , Myriad Genetics, Inc. announced its financial results for the three months ended December 31, 2025. The earnings release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements . Except for historical information contained in this Current Report on Form 8-K, including Exhibit 99.1, this Current Report on Form 8-K, includ…

Results of Operations and Financial Condition. On January 12, 2026, Myriad Genetics, Inc. (the “Company”) issued a press release announcing its preliminary revenue for the quarter and full year ended December 31, 2025. The Company also introduced full year 2026 financial guidance. In addition, the Company is announcing certain preliminary volume information for the full year ended December 31, 2025. Specifically, the Company expects total test volumes in 2025 of approximately 1.5 million, a 1…

Results of Operations and Financial Condition. On November 3, 2025, Myriad Genetics, Inc. (“Myriad”) furnished a Current Report on Form 8-K that included a press release reporting financial results for the three months ended September 30, 2025 (the "Original Form 8-K"). Myriad is filing this Amendment No. 1 on Form 8-K/A to amend the Original Form 8-K solely to correct the amount shown for Cash, cash equivalents, and restricted cash at beginning of the period for the three months ended Septem…

Results of Operations and Financial Condition. On November 3, 2025 Myriad Genetics, Inc. announced its financial results for the three months ended September 30, 2025. The earnings release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements . Except for historical information contained in this Current Report on Form 8-K, including Exhibit 99.1, this Current Report on Form 8-K, includin…

Chief Financial Officer — Scott J. Leffler: Mr. Leffler departed as Chief Financial Officer with a severance package.

Principal Accounting Officer — Natalie Munk: Natalie Munk resigned as Principal Accounting Officer, and Benjamin R. Wheeler was appointed to the role.

Chief Financial Officer — Scott J. Leffler: Scott J. Leffler departed as Chief Financial Officer, and Ben R. Wheeler was internally promoted to the role.

Results of Operations and Financial Condition. On August 5, 2025 Myriad Genetics, Inc. announced its financial results for the three months ended June 30, 2025. The earnings release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements . Except for historical information contained in this Current Report on Form 8-K, including Exhibit 99.1, this Current Report on Form 8-K, including Exhib…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information contained in

Entry into a Material Definitive Agreement. On July 31, 2025 (the “Closing Date”), Myriad Genetics, Inc. (the “Company”) entered into a Credit Agreement (the “Credit Agreement”) with the lenders from time to time party thereto (“Lenders”), and OrbiMed Royalty & Credit Opportunities IV, LP, as administrative agent (in such capacity, “Administrative Agent”) and as initial lender, consisting of a $200 million term loan credit facility with an initial term loan (the “Initial Loan”) in a maximum p…

Other Events. On July 31, 2025, the Company issued a press release announcing the entry into the Credit Agreement which is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The filing is about amendments to the equity incentive plan and does not involve any management changes.

Results of Operations and Financial Condition. On May 6, 2025, Myriad Genetics, Inc. ("Myriad" or the “Company”) announced its financial results for the three months ended March 31, 2025. The earnings release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements . Except for historical information contained in this Current Report on Form 8-K, including Exhibit 99.1, this Current Report o…

President, Chief Executive Officer and Director — Paul J. Diaz: Paul J. Diaz is stepping down to join a private equity firm but will continue as a consultant.

Results of Operations and Financial Condition. On February 24, 2025, Myriad Genetics, Inc. ("Myriad" or the “Company”) announced its financial results for the three months ended December 31, 2024. The earnings release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

Results of Operations and Financial Condition. On January 15, 2025, Myriad Genetics, Inc. (the “Company”) issued a press release announcing its preliminary revenue, loss per share and adjusted earnings per share results for the quarter and full year ended December 31, 2024 and cash and cash equivalents as of December 31, 2024. The Company also introduced full year 2025 financial guidance. The full text of the press release is furnished as Exhibit 99.1 hereto and incorporated herein by referen…